Chimeric antigen receptor-engineered adoptive cell therapy for AML: Current status and future perspectives

Immunomedicine Pub Date : 2022-01-19 DOI:10.1002/imed.1031
Yue Huang, Mi Shao, Yiyun Wang, He Huang
{"title":"Chimeric antigen receptor-engineered adoptive cell therapy for AML: Current status and future perspectives","authors":"Yue Huang,&nbsp;Mi Shao,&nbsp;Yiyun Wang,&nbsp;He Huang","doi":"10.1002/imed.1031","DOIUrl":null,"url":null,"abstract":"<p>Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B-cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor-based cell therapy in AML preclinical studies and clinical trials with potential AML-associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor-based cell therapy options for patients with AML.</p>","PeriodicalId":73348,"journal":{"name":"Immunomedicine","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imed.1031","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunomedicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imed.1031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B-cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor-based cell therapy in AML preclinical studies and clinical trials with potential AML-associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor-based cell therapy options for patients with AML.

Abstract Image

嵌合抗原受体工程过继细胞治疗AML:现状和未来展望
急性髓系白血病(AML)是一种复发率高、预后差的致死性血液系统恶性肿瘤。由于嵌合抗原受体细胞疗法在b细胞恶性肿瘤中表现出显著的治疗效果,许多研究试图将这一成功转化为其他恶性肿瘤,包括AML。在此,我们回顾了目前基于嵌合抗原受体的细胞治疗在AML临床前研究和潜在AML相关细胞标志物的临床试验中的成就。此外,我们讨论了嵌合抗原受体为基础的细胞治疗AML患者的未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信